steve_turley_linkedin

UCB appoints Steve Turley as MD for Britain and Ireland

pharmafile | November 18, 2015 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing UCB 

Steve Turley has joined UCB as the company’s managing director for the British and Irish isles, moving from Lundbeck.

He will also be an integral member of UCB’s European leadership team, reporting toKhoso Baluch, who is UCB’s head of EMEA operations.

Turley brings with him over 20 years of commercial experience in the biopharmaceutical industry gained at MSD, Roche, Actelion and most recently at Lundbeck. He has worked across a range of primary and specialty therapy areas at both local and international levels.

Turley’s career began as a sales representative with MSD, before moving to Roche where he held senior roles in marketing as business unit director. He went on to become general manager at Actelion and in the past five years was managing director at Lundbeck UK and Ireland. In addition to bringing his strong commercial leadership experience to UCB, his significant experience in market access and healthcare policy will be of great benefit to UCB.

Advertisement

Commenting on his appointment Turley says: “I am pleased to be joining a dynamic business that is focused on delivering medicines that really deliver for patients.  I am looking forward to building on that with our team here.”

Related Content

UCB presents positive results for fenfluramine in CDKL5 deficiency disorder

UCB has announced positive results from its phase 3 GEMZ study, showing that fenfluramine can …

UCB announces first-in-patient trial success for galvokimig in atopic dermatitis

UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults …

Rare and severe epilepsies – current treatments and advance therapeutics

The current forms of immunotherapy, how T cell therapy works and what the future holds

The Gateway to Local Adoption Series

Latest content